SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

RPG Life Sciences partners with Archerchem

13 Jul 2026 Evaluate

RPG Life Sciences has partnered with Archerchem Healthcare (Archerchem) to launch Naproxen and Esomeprazole combination for the first time in India by strengthening the existing business relationship with Archerchem. Naprosyn ES is a combination of Naproxen and Esomeprazole, designed to deliver effective anti-inflammatory solution along with gastroprotection. The combination has been co-developed by Archerchem along with its development partner. The company will exclusively market and distribute Naprosyn ES across the country and Archerchem as the exclusive supplier.

The product addresses a significant unmet need in patients requiring long-term Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy, particularly those at risk of gastrointestinal complications. The differentiated formulation is expected to improve patient compliance and enable safer long-term pain management, especially among elderly and gastro-sensitive populations.

The company will leverage the strong legacy and brand recall of Naprosyn brand and lean on its robust reach to a wide spectrum of doctors, including super-specialists, along with Pan-India distribution network to drive distribution. The launch aligns with the company’s continued focus on building a differentiated portfolio in chronic therapy segments.

RPG Life Sciences is an integrated research-based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company produces a wide range of quality and affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Life Sciences Share Price

2976.95 234.00 (8.53%)
15-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1952.45
Dr. Reddys Labs. 1229.80
Cipla 1437.95
Lupin 2491.80
Zydus Lifesciences 1154.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: